WAS
PTLA

WESPAC Advisors SoCal’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

WESPAC Advisors SoCal’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-300
Closed -$15K – 334
2015
Q4 		$15K Buy
+300
New +$14.5K 0.01% 174

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

WESPAC Advisors SoCal's PTLA Position: Q1 2016 in Review

WESPAC Advisors SoCal sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 300 shares — an estimated $15K sold.

WESPAC Advisors SoCal first reported a position in PTLA in Q4 2015 and held it in 1 quarter. The position peaked at $15K in Q4 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

  • WESPAC Advisors SoCal reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 300 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $15K.
  • WESPAC Advisors SoCal first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • WESPAC Advisors SoCal's Portola Pharmaceuticals, Inc. position peaked at $15K in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on WESPAC Advisors SoCal's 13F filing for Q1 2016, filed 12 Aug 2016.